文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

酒精使用障碍的药物治疗:系统综述与Meta分析

Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA · 2023-01-01

该系统综述与Meta分析纳入118项临床试验共20976名参与者,比较酒精使用障碍各疗法的疗效。结果显示,阿坎酸和口服纳曲酮50 mg/d在预防复饮方面具有中等以上证据强度,需治疗人数分别为11和18;口服纳曲酮50 mg/d还降低重度饮酒复发率(需治疗人数11)。结论支持在心理社会干预基础上将口服纳曲酮50 mg/d和阿坎酸作为一线药物治疗。

要点

  • 阿坎酸预防任何复饮的需治疗人数为11(95%CI,1-32),口服纳曲酮50 mg/d为18(95%CI,4-32)。
  • 口服纳曲酮50 mg/d降低重度饮酒复发率,需治疗人数为11(95%CI,5-41)。
  • 与安慰剂相比,阿坎酸腹泻风险比为1.58(95%CI,1.27-1.97),纳曲酮恶心风险比为1.73(95%CI,1.51-1.98)。

核心结论

  • 在心理社会干预基础上,这些发现支持将口服纳曲酮50 mg/d和阿坎酸作为酒精使用障碍的一线药物治疗。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Cochrane Library、Cochrane Central Trials Registry、PsycINFO、CINAHL和EMBASE从2012年11月至2022年9月9日的文献,并系统监测至2023年8月14日,PubMed检索于2023年8月14日更新。
  • 疗效结局纳入至少12周随机临床试验;不良效应纳入比较药物疗法并报告健康结局或伤害的随机临床试验和前瞻性队列研究。
  • 两名评价者评估每项研究、评估偏倚风险并分级证据强度,Meta分析采用随机效应模型,对至少中等证据强度获益的药物计算需治疗人数。
  • 共纳入118项临床试验、20976名参与者的数据。

主要发现

  • 预防1人任何复饮的需治疗人数:阿坎酸为11(95%CI,1-32),口服纳曲酮50 mg/d为18(95%CI,4-32)。
  • 与安慰剂相比,口服纳曲酮50 mg/d与较低的重度饮酒复发率相关,需治疗人数为11(95%CI,5-41)。
  • 注射用纳曲酮与30天治疗期内较少的饮酒天数相关(加权均数差,-4.99天;95%CI,-9.49至-0.49天)。
  • 与安慰剂相比,阿坎酸胃肠道不适更高(腹泻:风险比1.58;95%CI,1.27-1.97),纳曲酮胃肠道不适更高(恶心:风险比1.73;95%CI,1.51-1.98;呕吐:风险比1.53;95%CI,1.23-1.91)。

关键数值与推荐

  • 阿坎酸预防任何复饮的需治疗人数为11(95%CI,1-32),口服纳曲酮50 mg/d为18(95%CI,4-32)。
  • 口服纳曲酮50 mg/d预防重度饮酒复发的需治疗人数为11(95%CI,5-41)。
  • 注射用纳曲酮30天治疗期内饮酒天数的加权均数差为-4.99天(95%CI,-9.49至-0.49天)。
  • 阿坎酸腹泻风险比1.58(95%CI,1.27-1.97);纳曲酮恶心风险比1.73(95%CI,1.51-1.98),呕吐风险比1.53(95%CI,1.23-1.91)。

临床怎么用

  • 作者结论认为,在心理社会干预基础上,这些发现支持使用口服纳曲酮50 mg/d和阿坎酸作为酒精使用障碍的一线药物治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alcohol use disorder affects more than 28.3 million people in the United States and is associated with increased rates of morbidity and mortality. OBJECTIVE: To compare efficacy and comparative efficacy of therapies for alcohol use disorder. DATA SOURCES: PubMed, the Cochrane Library, the Cochrane Central Trials Registry, PsycINFO, CINAHL, and EMBASE were searched from November 2012 to September 9, 2022 Literature was subsequently systematically monitored to identify relevant articles up to August 14, 2023, and the PubMed search was updated on August 14, 2023. STUDY SELECTION: For efficacy outcomes, randomized clinical trials of at least 12 weeks' duration were included. For adverse effects, randomized clinical trials and prospective cohort studies that compared drug therapies and reported health outcomes or harms were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers evaluated each study, assessed risk of bias, and graded strength of evidence. Meta-analyses used random-effects models. Numbers needed to treat were calculated for medications with at least moderate strength of evidence for benefit. MAIN OUTCOMES AND MEASURES: The primary outcome was alcohol consumption. Secondary outcomes were motor vehicle crashes, injuries, quality of life, function, mortality, and harms. RESULTS: Data from 118 clinical trials and 20 976 participants were included. The numbers needed to treat to prevent 1 person from returning to any drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) for oral naltrexone at a dose of 50 mg/d. Compared with placebo, oral naltrexone (50 mg/d) was associated with lower rates of return to heavy drinking, with a number needed to treat of 11 (95% CI, 5-41). Injectable naltrexone was associated with fewer drinking days over the 30-day treatment period (weighted mean difference, -4.99 days; 95% CI, -9.49 to -0.49 days) Adverse effects included higher gastrointestinal distress for acamprosate (diarrhea: risk ratio, 1.58; 95% CI, 1.27-1.97) and naltrexone (nausea: risk ratio, 1.73; 95% CI, 1.51-1.98; vomiting: risk ratio, 1.53; 95% CI, 1.23-1.91) compared with placebo. CONCLUSIONS AND RELEVANCE: In conjunction with psychosocial interventions, these findings support the use of oral naltrexone at 50 mg/d and acamprosate as first-line pharmacotherapies for alcohol use disorder.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023. PMID: 37934220. doi:10.1001/jama.2023.19761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。